Search results
Showing 181 to 195 of 971 results for death
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Bioresorbable stent implantation to treat coronary artery disease (IPG732)
Evidence-based recommendations on bioresorbable stent implantation to treat coronary artery disease in adults. This involves implanting a stent (small tube) into a narrowed artery to widen it.
View recommendations for IPG732Show all sections
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.
longer term. This includes an increased risk of myocardial infarction and death with some types of bioresorbable stents. Therefore, this...
Palforzia for treating peanut allergy in children and young people (TA769)
Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people.
Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.
Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.